JY
PHAT icon

Jeff Yass’s Phathom Pharmaceuticals PHAT Stock Holding History

Jeff Yass’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Sell
210,300
-113,500
-35% -$1.3M ﹤0.01% 6178
2026
Q1 		$3.6M Buy
323,800
+6,200
+2% +$78.3K ﹤0.01% 4880
2025
Q4 		$5.27M Buy
317,600
+262,300
+474% +$3.75M ﹤0.01% 3934
2025
Q3 		$651K Sell
55,300
-499,600
-90% -$5.16M ﹤0.01% 8375
2025
Q2 		$5.32M Buy
554,900
+524,600
+1,731% +$2.9M ﹤0.01% 3861
2025
Q1 		$190K Buy
30,300
+4,400
+17% +$26.7K ﹤0.01% 10988
2024
Q4 		$210K Buy
25,900
+3,100
+14% +$38.4K ﹤0.01% 10627
2024
Q3 		$412K Sell
22,800
-440,100
-95% -$6.15M ﹤0.01% 8934
2024
Q2 		$4.77M Buy
462,900
+448,800
+3,183% +$4.62M ﹤0.01% 3518
2024
Q1 		$150K Buy
14,100
+1,300
+10% +$11K ﹤0.01% 10906
2023
Q4 		$117K Sell
12,800
-68,400
-84% -$589K ﹤0.01% 11202
2023
Q3 		$842K Sell
81,200
-71,200
-47% -$977K ﹤0.01% 7029
2023
Q2 		$2.18M Sell
152,400
-39,300
-21% -$453K ﹤0.01% 4974
2023
Q1 		$1.37M Buy
+191,700
New +$1.68M ﹤0.01% 6023
2022
Q4 		– Sell
-76,100
Closed -$843K – 13369
2022
Q3 		$843K Buy
76,100
+600
+0.8% +$5.72K ﹤0.01% 7084
2022
Q2 		$637K Buy
75,500
+40,600
+116% +$417K ﹤0.01% 7671
2022
Q1 		$475K Buy
+34,900
New +$564K ﹤0.01% 9125
2021
Q3 		– Sell
-10,000
Closed -$339K – 13352
2021
Q2 		$339K Buy
+10,000
New +$358K ﹤0.01% 10504
2021
Q1 		– Sell
-10,800
Closed -$359K – 12690
2020
Q4 		$359K Buy
+10,800
New +$438K ﹤0.01% 8924

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Jeff Yass's PHAT Position: Q2 2026 in Review

Jeff Yass reduced its Phathom Pharmaceuticals (PHAT) stake by 81% in Q2 2026, selling an estimated $859K and leaving 17,725 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #11993.

Jeff Yass first reported a position in PHAT in Q4 2020 and has held it in 16 quarters since. The position peaked at $9.11M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Jeff Yass held 17,725 shares of Phathom Pharmaceuticals worth $192K as of Q2 2026.
  • Jeff Yass sold 75,254 Phathom Pharmaceuticals shares in Q2 2026, an estimated $859K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11993 holding.
  • Jeff Yass first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
  • Jeff Yass's Phathom Pharmaceuticals position peaked at $9.11M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.